Moreover, compelling evidence from experimental models has underscored the therapeutic potential of selective PTGS2 inhibitors such as celecoxib in impeding gastric tumor development, offering promising avenues for targeted intervention strategies in the realm of gastric cancer therapeutics [36]. The gene discussed is PTGS2; the disease is gastric cancer.